Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down – What’s Next?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) gapped down prior to trading on Thursday . The stock had previously closed at $13.18, but opened at $12.89. Y-mAbs Therapeutics shares last traded at $12.32, with a volume of 25,075 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on YMAB. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley cut their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. Finally, BMO Capital Markets decreased their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Stock Performance

The stock has a fifty day moving average price of $14.08 and a 200-day moving average price of $13.13. The firm has a market cap of $538.81 million, a PE ratio of -22.50 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the firm posted ($0.18) earnings per share. As a group, equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Thomas Gad sold 65,000 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the sale, the insider now owns 97,681 shares in the company, valued at approximately $1,315,763.07. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock in a transaction on Friday, September 13th. The shares were sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the sale, the insider now directly owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock worth $1,338,100 over the last three months. Corporate insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its holdings in Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after acquiring an additional 67,233 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Y-mAbs Therapeutics by 9.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock valued at $3,676,000 after purchasing an additional 23,982 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after purchasing an additional 8,974 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.